S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
Log in
NASDAQ:ILMN

Illumina Stock Forecast, Price & News

$439.41
-6.45 (-1.45 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$432.06
Now: $439.41
$445.98
50-Day Range
$361.28
MA: $430.18
$504.76
52-Week Range
$196.78
Now: $439.41
$555.77
Volume1.45 million shs
Average Volume1.23 million shs
Market Capitalization$64.11 billion
P/E Ratio101.95
Dividend YieldN/A
Beta1.14
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. has a strategic collaboration with Myriad Genetics, Inc. to create a kit-based version of the myChoice companion diagnostic test for international markets. The company was founded in 1998 and is headquartered in San Diego, California.
Illumina logo

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:ILMN
CUSIP45232710
Phone858-202-4500
Employees7,700
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.54 billion
Cash Flow$9.99 per share
Book Value$31.38 per share

Profitability

Net Income$1.00 billion

Miscellaneous

Market Cap$64.11 billion
Next Earnings Date4/29/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.65 out of 5 stars

Medical Sector

294th out of 1,960 stocks

Analytical Instruments Industry

7th out of 29 stocks

Analyst Opinion: 2.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$439.41
-6.45 (-1.45 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ILMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Illumina (NASDAQ:ILMN) Frequently Asked Questions

Is Illumina a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 3 sell ratings, 8 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Illumina stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View analyst ratings for Illumina
or view top-rated stocks.

What stocks does MarketBeat like better than Illumina?

Wall Street analysts have given Illumina a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Illumina wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Illumina?

Illumina saw a drop in short interest in the month of January. As of January 29th, there was short interest totaling 4,150,000 shares, a drop of 19.1% from the January 14th total of 5,130,000 shares. Based on an average daily volume of 1,110,000 shares, the days-to-cover ratio is presently 3.7 days. Approximately 2.9% of the company's shares are short sold.
View Illumina's Short Interest
.

When is Illumina's next earnings date?

Illumina is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Illumina
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) released its quarterly earnings data on Thursday, February, 11th. The life sciences company reported $1.22 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.11 by $0.11. Illumina had a net margin of 19.70% and a trailing twelve-month return on equity of 15.93%.
View Illumina's earnings history
.

How has Illumina's stock been impacted by Coronavirus (COVID-19)?

Illumina's stock was trading at $246.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ILMN stock has increased by 78.6% and is now trading at $439.41.
View which stocks have been most impacted by COVID-19
.

What guidance has Illumina issued on next quarter's earnings?

Illumina updated its FY 2021 After-Hours earnings guidance on Thursday, February, 11th. The company provided EPS guidance of 5.10-5.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.11. The company issued revenue guidance of $3.79-3.887 billion, compared to the consensus revenue estimate of $3.9 billion.

What price target have analysts set for ILMN?

18 equities research analysts have issued twelve-month price objectives for Illumina's shares. Their forecasts range from $280.00 to $570.00. On average, they anticipate Illumina's share price to reach $365.32 in the next twelve months. This suggests that the stock has a possible downside of 16.9%.
View analysts' price targets for Illumina
or view top-rated stocks among Wall Street analysts.

Who are Illumina's key executives?

Illumina's management team includes the following people:
  • Mr. Francis A. deSouza, CEO, Pres & Director (Age 50)
  • Mr. Sam A. Samad, CFO & Sr. VP (Age 51, Pay $626.7k)
  • Dr. Joydeep Goswami, Sr. VP of Corp. Devel. & Strategic Planning (Age 50, Pay $384.38k)
  • Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 50, Pay $864.07k)
  • Mr. Robert P. Ragusa, Sr. VP of Global Quality & Operations (Age 61)
  • Ms. Karen K. McGinnis, VP & Chief Accounting Officer (Age 54)
  • Dr. Alexander Aravanis M.D., Ph.D., Sr. VP & Chief Technology Officer
  • Mr. Steve Phillpott, Sr. VP & Chief Information Officer
  • Ms. Juliet Cunningham, VP of Investor Relations
  • Mr. Charles E. Dadswell, Sr. VP, Gen. Counsel & Sec. (Age 62)

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina CEO Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among Illumina's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Illumina's key competitors?

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), The Walt Disney (DIS), PayPal (PYPL), salesforce.com (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (13.59%), Edgewood Management LLC (4.76%), Sands Capital Management LLC (2.02%), Janus Henderson Group PLC (1.88%), Northern Trust Corp (1.14%) and Alliancebernstein L.P. (0.88%). Company insiders that own Illumina stock include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi.
View institutional ownership trends for Illumina
.

Which major investors are selling Illumina stock?

ILMN stock was sold by a variety of institutional investors in the last quarter, including Select Equity Group L.P., WCM Investment Management LLC, WCM Investment Management LLC, Sumitomo Mitsui Trust Holdings Inc., Swedbank, First Trust Advisors LP, Principal Financial Group Inc., and Principal Financial Group Inc.. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Phillip G Febbo, Robert P Ragusa, Sam Samad, and Susan H Tousi.
View insider buying and selling activity for Illumina
or view top insider-selling stocks.

Which major investors are buying Illumina stock?

ILMN stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Janus Henderson Group PLC, Ownership Capital B.V., Korea Investment CORP, Ardevora Asset Management LLP, Northern Trust Corp, Ensemble Capital Management LLC, and Bamco Inc. NY.
View insider buying and selling activity for Illumina
or or view top insider-buying stocks.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $439.41.

How much money does Illumina make?

Illumina has a market capitalization of $64.11 billion and generates $3.54 billion in revenue each year. The life sciences company earns $1.00 billion in net income (profit) each year or $6.57 on an earnings per share basis.

How many employees does Illumina have?

Illumina employs 7,700 workers across the globe.

What is Illumina's official website?

The official website for Illumina is www.illumina.com.

Where are Illumina's headquarters?

Illumina is headquartered at 200 ILLUMINA WAY, SAN DIEGO CA, 92122.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]


This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.